Statements (141)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
gptkb:diabetes |
| gptkbp:administered_by |
before meals
inhalation |
| gptkbp:approves |
gptkb:2014
gptkb:Canada gptkb:European_Union gptkb:FDA gptkb:United_States |
| gptkbp:availability |
pharmacies
prescription only |
| gptkbp:available_in |
cartridge form
|
| gptkbp:can_be_prescribed_by |
primary care physicians
endocrinologists |
| gptkbp:can_be_used_with |
gptkb:metformin
GLP-1 receptor agonists sulfonylureas |
| gptkbp:can_cause |
allergic reactions
weight gain |
| gptkbp:clinical_trial |
conducted
Phase 3 trials ongoing studies published in medical journals studies on efficacy positive outcomes reported AFREZZA clinical trials |
| gptkbp:clinical_use |
gptkb:Type_1_diabetes
Type 2 diabetes blood glucose control |
| gptkbp:community_health |
necessary for safe use
training on use |
| gptkbp:competitors |
other insulin products
|
| gptkbp:contains |
gptkb:diabetes
|
| gptkbp:contraindication |
gptkb:asthma
COPD smoking chronic lung disease |
| gptkbp:customer_satisfaction |
varies among users
|
| gptkbp:developed_by |
gptkb:Mann_Kind_Corporation
|
| gptkbp:dosage_form |
powder
inhalation powder |
| gptkbp:drug_interactions |
beta-blockers
other antidiabetic medications thiazolidinediones |
| gptkbp:duration |
2-3 hours
short |
| gptkbp:educational_resources |
provided to patients
|
| gptkbp:feedback |
mixed reviews
important for improvement |
| gptkbp:financial_support |
available through manufacturer
monitor blood sugar levels Mann Kind support programs |
| gptkbp:form |
inhalation powder
|
| gptkbp:formulation |
powder
dry powder |
| gptkbp:funding |
supported by grants
|
| gptkbp:future_prospects |
long-term effects
|
| gptkbp:has_limitations |
not for DKA treatment
|
| gptkbp:healthcare |
impact on diabetes management
|
| gptkbp:healthcare_provider_recommendation |
considered for some patients
|
| https://www.w3.org/2000/01/rdf-schema#label |
AFREZZA®
|
| gptkbp:indication |
mealtime insulin therapy
postprandial glucose control |
| gptkbp:ingredients |
gptkb:diabetes
|
| gptkbp:inhalation_device |
gptkb:Dreamboat_inhaler
|
| gptkbp:interacts_with |
other diabetes medications
|
| gptkbp:invention |
patented
|
| gptkbp:is |
a replacement for long-acting insulin
for diabetic ketoacidosis for type 1 diabetes |
| gptkbp:is_a_guide_for |
recommended for Type 1 Diabetes
|
| gptkbp:is_available_in |
various dosages
|
| gptkbp:is_considered |
insulin pump use
alternative to injections convenient for some patients |
| gptkbp:is_effective_against |
effective for mealtime insulin
|
| gptkbp:is_monitored_by |
blood glucose levels
|
| gptkbp:is_part_of |
diabetes management plan
|
| gptkbp:is_subject_to |
insurance coverage
prior authorization |
| gptkbp:is_used_in |
pediatric patients
adult patients |
| gptkbp:manufacturer |
gptkb:Mann_Kind_Corporation
|
| gptkbp:marketed_as |
gptkb:2014
gptkb:Canada gptkb:European_Union gptkb:United_States easy to use rapid-acting insulin non-injection option |
| gptkbp:marketing_strategy |
focus on convenience
|
| gptkbp:notable_technology |
inhaler device
|
| gptkbp:packaging |
gptkb:Spider-Man
inhaler device |
| gptkbp:patient_education |
inhalation technique
|
| gptkbp:patient_population |
diverse population
adults with diabetes adults and children with Type 1 Diabetes |
| gptkbp:pharmacokinetics |
rapid onset of action
rapid absorption insulin action mimics physiological insulin secretion |
| gptkbp:premiered_on |
rapid
approximately 12-15 minutes |
| gptkbp:price |
varies by insurance
|
| gptkbp:provides_guidance_on |
gptkb:diabetes
updated regularly not recommended for children recommended for adults |
| gptkbp:regulatory_compliance |
prescription medication
received in 2014 |
| gptkbp:requires |
available online
patient education inhaler device |
| gptkbp:research_focus |
diabetes management
|
| gptkbp:route_of_administration |
inhalation
|
| gptkbp:safety |
included with packaging
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:service_frequency |
at mealtimes
|
| gptkbp:shelf_life |
2 years
|
| gptkbp:side_effect |
fatigue
headache nausea allergic reactions cough hypoglycemia throat irritation lung function decline |
| gptkbp:storage |
room temperature
|
| gptkbp:suitable_for |
gptkb:children
pregnant women smokers |
| gptkbp:treatment |
improved glycemic control
improved postprandial glucose |
| gptkbp:type_of_care |
important for effectiveness
critical for effectiveness |
| gptkbp:type_of_insurance |
varies by plan
|
| gptkbp:used_for |
gptkb:diabetes
gptkb:Type_1_Diabetes treatment of diabetes |
| gptkbp:user_reviews |
mixed feedback
|